AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
tegaserod 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| serotonin receptor antagonists and partial agonists | 2579 | 145158-71-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
a nonbenzamide 5-hydroxytryptamine(4) agonist; used in treatment of irritable bowel syndrome; marketing suspended 2007 in US due to higher incidence of MI, stroke, and unstable angina; structure given in first source
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 12 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.66 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 11 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 5.30 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 18 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.02 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 11 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT1,AKT2,AKT3,ALK,AURKA,AURKB,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK4,CDK5,CDK9,CHEK1,CSF1R,DDR1,DYRK1B,EIF2AK3,EPHA2,EPHB4,ERBB2,FGFR1,FLT3,GRK1,GRK2,GRK3,GSK3B,IGF1R,INSR,IRAK1,ITK,JAK1,JAK2,JAK3,KIT,MAP2K6,MAP3K1,MAP3K10,MAP3K11,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK1,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MELK,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PLK1,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,TYRO3,ULK1,ULK2,ZAP70 | 85 | |||
| kinase-selectivity-class | AXL,BRAF,CAMK2D,DDR1,DYRK1B,EIF2AK3,EPHB4,GRK2,MAP2K6,MAPK7,PDK1,PDK4,SIK2,STK33,TEK,TTK | 16 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 24, 2002 | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A06AX06 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR CONSTIPATION DRUGS FOR CONSTIPATION Other drugs for constipation |
| MeSH PA | D017366 | Serotonin Receptor Agonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018490 | Serotonin Agents |
| FDA MoA | N0000193870 | Serotonin 4 Receptor Agonists |
| FDA EPC | N0000193871 | Serotonin-4 Receptor Agonist |
| CHEBI has role | CHEBI:35941 | serotonergic agonist |
| CHEBI has role | CHEBI:50503 | laxative |
| CHEBI has role | CHEBI:55324 | gastrointestinal drug |
Related Drugs by ATC class:
A06AX Other drugs for constipation 7 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Chronic idiopathic constipation | indication | 82934008 | |
| Irritable bowel syndrome characterized by constipation | indication | 440630006 | |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Hypovolemia | contraindication | 28560003 | |
| Ischemic colitis | contraindication | 30588004 | DOID:0060181 |
| Dehydration | contraindication | 34095006 | |
| Disorder of gallbladder | contraindication | 39621005 | DOID:0060262 |
| Acute nephropathy | contraindication | 58574008 | |
| Diarrhea | contraindication | 62315008 | |
| Intestinal obstruction | contraindication | 81060008 | DOID:8437 |
| Disorder of biliary tract | contraindication | 105997008 | DOID:9741 |
| Angina pectoris | contraindication | 194828000 | |
| Cerebrovascular accident | contraindication | 230690007 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Adhesion of Gastrointestinal Tract | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.67 | acidic |
| pKa2 | 12.01 | Basic |
| pKa3 | 1.56 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | GPCR | PARTIAL AGONIST | Ki | 8.40 | CHEMBL | CHEMBL | |||
| Beta-1 adrenergic receptor | GPCR | Ki | 5.40 | CHEMBL | |||||
| Mu-type opioid receptor | GPCR | Ki | 5.55 | CHEMBL | |||||
| D(2) dopamine receptor | GPCR | Ki | 6.53 | CHEMBL | |||||
| Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 6.75 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 7.08 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 3A | Ion channel | Ki | 5.60 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | Ki | 6.37 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 2B | GPCR | ANTAGONIST | Ki | 8.40 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 2C | GPCR | Ki | 6.85 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 6 | GPCR | Ki | 6.25 | CHEMBL | |||||
| Alpha-1A adrenergic receptor | GPCR | Ki | 5.79 | CHEMBL | |||||
| Alpha-2B adrenergic receptor | GPCR | Ki | 5.55 | CHEMBL | |||||
| D(3) dopamine receptor | GPCR | Ki | 6.37 | CHEMBL | |||||
| D(1B) dopamine receptor | GPCR | Ki | 5.38 | CHEMBL | |||||
| Beta-3 adrenergic receptor | GPCR | Ki | 5.31 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1D | GPCR | Ki | 7.30 | CHEMBL | |||||
| D(4) dopamine receptor | GPCR | Ki | 6.72 | CHEMBL | |||||
| Alpha-1D adrenergic receptor | GPCR | Ki | 5.79 | CHEMBL | |||||
| Alpha-1B adrenergic receptor | GPCR | Ki | 5.58 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 5A | GPCR | Ki | 6.70 | CHEMBL | |||||
| Transmembrane protein 97 | Enzyme | Ki | 7.24 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 4 | GPCR | EC50 | 7.90 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4021352 | VUID |
| N0000148771 | NUI |
| D02730 | KEGG_DRUG |
| 4021352 | VANDF |
| 4024281 | VANDF |
| CHEBI:51043 | CHEBI |
| A1IVL | PDB_CHEM_ID |
| CHEMBL76370 | ChEMBL_ID |
| CHEMBL1516474 | ChEMBL_ID |
| C105050 | MESH_SUPPLEMENTAL_RECORD_UI |
| 226 | IUPHAR_LIGAND_ID |
| 189188-57-6 | SECONDARY_CAS_RN |
| DB01079 | DRUGBANK_ID |
| 458VC51857 | UNII |
| 139778 | RXNORM |
| 16842 | MMSL |
| 43157 | MMSL |
| d04798 | MMSL |
| 009658 | NDDF |
| 386035006 | SNOMEDCT_US |
| 386036007 | SNOMEDCT_US |
| 417025001 | SNOMEDCT_US |
| C0537147 | UMLSCUI |
| 7606 | INN_ID |
| 135409453 | PUBCHEM_CID |
| 458VC51857 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| ZELNORM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0525-0971 | TABLET | 6 mg | ORAL | NDA | 27 sections |